TWI335229B - - Google Patents
Download PDFInfo
- Publication number
- TWI335229B TWI335229B TW93112112A TW93112112A TWI335229B TW I335229 B TWI335229 B TW I335229B TW 93112112 A TW93112112 A TW 93112112A TW 93112112 A TW93112112 A TW 93112112A TW I335229 B TWI335229 B TW I335229B
- Authority
- TW
- Taiwan
- Prior art keywords
- arsenic
- cancer
- pharmaceutical composition
- skin
- containing pharmaceutical
- Prior art date
Links
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 36
- 229910052785 arsenic Inorganic materials 0.000 claims description 31
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 238000001959 radiotherapy Methods 0.000 claims description 22
- 208000037819 metastatic cancer Diseases 0.000 claims description 17
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 17
- 230000005855 radiation Effects 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229910052958 orpiment Inorganic materials 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 48
- 238000011282 treatment Methods 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 6
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010894 electron beam technology Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000000779 thoracic wall Anatomy 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010018690 Granulocytosis Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 206010048629 Wound secretion Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 208000006934 radiodermatitis Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 2
- 241001508687 Mustela erminea Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100037101 Deoxycytidylate deaminase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000955042 Homo sapiens Deoxycytidylate deaminase Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 150000001495 arsenic compounds Chemical class 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093920 gynecological arsenic compound Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW093112112A TW200503798A (en) | 2004-04-30 | 2004-04-30 | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW093112112A TW200503798A (en) | 2004-04-30 | 2004-04-30 | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200503798A TW200503798A (en) | 2005-02-01 |
| TWI335229B true TWI335229B (enrdf_load_stackoverflow) | 2011-01-01 |
Family
ID=45075010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093112112A TW200503798A (en) | 2004-04-30 | 2004-04-30 | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200503798A (enrdf_load_stackoverflow) |
-
2004
- 2004-04-30 TW TW093112112A patent/TW200503798A/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200503798A (en) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| JP2005008534A (ja) | 抗癌剤及び癌の治療方法 | |
| JP6656397B2 (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
| Coughlin et al. | Platinum based combined modality approach for locally advanced head and neck carcinoma | |
| JPH0390025A (ja) | 抗腫瘍剤 | |
| CN116726021B (zh) | 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途 | |
| JPH0296524A (ja) | 抗癌活性を有する治療薬組成物と癌の治療方法 | |
| WO2015172712A1 (zh) | 维生素c与抗肿瘤药物协同作用的注射用药物组合物 | |
| Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
| JP7488588B2 (ja) | ワクシニアウイルスによって炎症を起こしたウサギ皮膚由来の抽出物のがん治療における使用 | |
| TWI335229B (enrdf_load_stackoverflow) | ||
| CN101167741B (zh) | 莱菔硫烷和铂类药的抗癌联合制剂 | |
| SA94140746B1 (ar) | مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان | |
| Shibata et al. | Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma | |
| CN111773388B (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| US20050208149A1 (en) | Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment | |
| CN114081880B (zh) | 木香内酯及其衍生物在制备预防和/或治疗肠损伤的药物中的用途 | |
| KR20100126453A (ko) | 조합 항암제 | |
| CN106668061B (zh) | 一种含有顺铂的抗癌药物组合物 | |
| CN115837042B (zh) | 当归补血汤在制备增强免疫检查点抑制剂疗效的药物中的应用 | |
| CN104667123B (zh) | 一种用于局部晚期胰腺癌三维适形调强放疗的中药组合物及其应用 | |
| WO2022151335A2 (zh) | 一种高压氧联合免疫药物用于肿瘤治疗的方法 | |
| Jortay et al. | Regional chemotherapy of maxillofacial malignant melanoma with intracarotid artery infusion of DTIC | |
| CN103860561B (zh) | 一种防治乳腺癌的药物组合物及其应用 | |
| Antonadou et al. | The prophylactic use of amifostine in the prevention of chemoradiation induced mucositis and xerostomia in head and neck cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |